State Street Corp Codiak Bio Sciences, Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.18 - $0.81 $8,702 - $39,162	-48,349 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$0.32 - $0.9 $2,240 - $6,300	-7,000 Reduced 12.65%	48,349 $19,000
Q2 2022 Aug 15, 2022	SELL	$2.24 - $6.96 $588,990 - $1.83 Million	-262,942 Reduced 82.61%	55,349 $159,000
Q1 2022 May 16, 2022	BUY	$4.3 - $12.95 $103,238 - $310,916	24,009 Added 8.16%	318,291 $2 Million
Q4 2021 Feb 14, 2022	BUY	$10.0 - $16.78 $270,470 - $453,848	27,047 Added 10.12%	294,282 $3.28 Million
Q3 2021 Nov 15, 2021	BUY	$15.58 - $22.88 $485,644 - $713,192	31,171 Added 13.2%	267,235 $4.36 Million
Q2 2021 Aug 16, 2021	BUY	$11.72 - $26.81 $1.79 Million - $4.09 Million	152,435 Added 182.28%	236,064 $4.37 Million
Q1 2021 May 17, 2021	BUY	$13.49 - $31.53 $223,596 - $522,609	16,575 Added 24.72%	83,629 $1.26 Million
Q4 2020 Feb 16, 2021	BUY	$7.9 - $32.3 $529,726 - $2.17 Million	67,054 New	67,054 $2.17 Million

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.